Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|April 27, 2024
Chemical Modifications to Enhance the Drug Properties of a VIP Receptor Antagonist (ANT) PeptideChristina Lester, Jian-Ming Li, Tenzin Passang, et al.
Frontiers in Immunology|May 8, 2023
The magic of small-molecule drugs during <i>ex vivo</i> expansion in adoptive cell therapyHanwen Zhang, Tenzin Passang, Sruthi Ravindranathan, et al.
Cancer Research|May 29, 2024
VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic CancerTenzin Passang, Shuhua Wang, Hanwen Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2025
Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell LymphomaFanyuan Zeng, Hanwen Zhang, Shuhua Wang, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activityYuou Wang, Anish Sen-Majumdar, Jian-Ming Li, et al.
Blood|April 20, 2022
Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expressionJingru Zhu, Yitong Wang, Jingxia Li, et al.
Cancer Letters|June 7, 2025
Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver MetastasisWenxi Wang, Hua Yang, Tenzin Passang, et al.
The Journal of Biological Chemistry|January 1, 2026
Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activityYuou Wang, Anish Sen-Majumdar, Jian-Ming Li, et al.
Nature Communications|October 27, 2022
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinomaSruthi Ravindranathan, Tenzin Passang, Jian-Ming Li, et al.
Pageof 1